The NF-κB (Nuclear Factor Kappa B) signaling pathway is a central regulator of neuroinflammation and cell survival in neurodegenerative diseases. While acute NF-κB activation is protective, chronic activation drives progressive neuroinflammation, synaptic dysfunction, and neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders[@shih2015]. NF-κB represents one of the most thoroughly studied yet therapeutically challenging targets in neurodegeneration research.
For comprehensive coverage including molecular mechanisms, therapeutic approaches, and detailed references, see [NF-κB Signaling in Neurodegeneration](/mechanisms/nfkb-signaling-neurodegeneration).
The NF-κB family consists of five closely related transcription factors that form various homo- and heterodimers:
| Member | Alternative Name | Dimer Partners | Key Roles |
|--------|-----------------|---------------|-----------|
| p65 (RelA) | RELA | p50, c-Rel, RelB | Pro-inflammatory gene activation |
| p50 | NFKB1 | p65, c-Rel | DNA binding, repression |
| c-Rel | REL | p50, p65 | Lymphoid development, survival |
| RelB | RELB | p52 | Non-canonical signaling |
| p52 | NFKB2 | RelB, p65 | Non-canonical pathway |
The most common dimers in the nervous system are p65/p50 (canonical) and RelB/p52 (non-canonical)[@kalinina2006].
The NF-κB (Nuclear Factor Kappa B) signaling pathway is a central regulator of neuroinflammation and cell survival in neurodegenerative diseases. While acute NF-κB activation is protective, chronic activation drives progressive neuroinflammation, synaptic dysfunction, and neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders[@shih2015]. NF-κB represents one of the most thoroughly studied yet therapeutically challenging targets in neurodegeneration research.
For comprehensive coverage including molecular mechanisms, therapeutic approaches, and detailed references, see [NF-κB Signaling in Neurodegeneration](/mechanisms/nfkb-signaling-neurodegeneration).
The NF-κB family consists of five closely related transcription factors that form various homo- and heterodimers:
| Member | Alternative Name | Dimer Partners | Key Roles |
|--------|-----------------|---------------|-----------|
| p65 (RelA) | RELA | p50, c-Rel, RelB | Pro-inflammatory gene activation |
| p50 | NFKB1 | p65, c-Rel | DNA binding, repression |
| c-Rel | REL | p50, p65 | Lymphoid development, survival |
| RelB | RELB | p52 | Non-canonical signaling |
| p52 | NFKB2 | RelB, p65 | Non-canonical pathway |
The most common dimers in the nervous system are p65/p50 (canonical) and RelB/p52 (non-canonical)[@kalinina2006].
The IκB kinase (IKK) complex serves as the master regulator of canonical NF-κB signaling. The complex comprises:
The canonical NF-kappaB pathway is activated by diverse pro-inflammatory stimuli including cytokines (TNF-alpha, IL-1beta), pathogen-associated molecular patterns (LPS), and disease-specific ligands such as Abeta oligomers and alpha-synuclein aggregates["@mattson2005"]. Receptor engagement triggers recruitment of adaptor proteins that ultimately activate the IKK complex. Activated IKK phosphorylates IkappaBalpha, targeting it for ubiquitination and proteasomal degradation. Freed p65/p50 dimers translocate to the nucleus where they bind specific kappaB DNA sequences and recruit coactivators (CBP/p300) to drive transcription of inflammatory, survival, and synaptic genes["@kaltschmidt2007"].
The non-canonical NF-κB pathway operates through a distinct mechanism controlled by NIK (NF-κB-inducing kinase) and proteolytic processing of p100[@sun2012]:
This pathway is critical for adaptive immune responses and is implicated in CNS autoimmunity and chronic neuroinflammation. In neurodegeneration, non-canonical signaling contributes to microglial polarization and T-cell infiltration across the blood-brain barrier.
The canonical NF-κB pathway is activated by pro-inflammatory cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (LPS), and cellular stress[@kiss2011]:
The alternative pathway uses NF-κB inducing kinase (NIK) to process p100 to p52, generating RelB/p52 dimers with distinct gene targets[@sun2012].
NF-κB is one of the earliest and most consistent findings in AD[@chen2012]:
NF-κB contributes to dopaminergic neuron loss[@ghosh2017]:
NF-κB drives motor neuron degeneration[@dresselhaus2020]:
NF-κB activation in brain endothelial cells contributes to BBB breakdown across neurodegenerative conditions. Pro-inflammatory cytokines activate NF-κB in endothelial cells, increasing expression of adhesion molecules (VCAM-1, ICAM-1) and chemokines that facilitate leukocyte transmigration. This is particularly relevant in MS, AD, and traumatic brain injury[@eissner2022].
ER stress and NF-κB are interconnected through multiple mechanisms[@ho2016]. The IRE1α branch of the unfolded protein response activates NF-κB via IKK, while PERK-eIF2α signaling cross-talks with the NF-κB pathway. In neurodegenerative conditions with significant protein misfolding (AD, PD, ALS), ER stress-mediated NF-κB activation drives chronic neuroinflammation.
| Approach | Examples | Status | Notes |
|----------|----------|--------|-------|
| IKK inhibitors | MLN120B, BAY 11-7082 | Preclinical | Broad immunosuppression |
| IκB stabilization | Bortezomib | Preclinical | Proteasome inhibitor |
| Natural products | Curcumin, Resveratrol | Clinical trials | Poor bioavailability |
| Cell-type delivery | Nanoparticles, viral vectors | Preclinical | Targeted approaches |
| Gene therapy | NF-κB decoys, siRNA | Preclinical | Experimental |
| Decoy oligos | NF-κB decoy nucleotides | Phase 2 | Topical/local delivery |
| TAK1 inhibitors | RK-33 | Preclinical | Dampens both pathways |
Emerging approaches aim to selectively modulate NF-κB in disease-relevant cell types:
NF-κB intersects with multiple neurodegeneration-relevant pathways:
NF-κB signaling sits at the intersection of neuroinflammation and neurodegeneration. The pathway's dual nature—both protective and pathogenic—creates a therapeutic paradox. Successful approaches will require cell-type-selective modulation, timing based on disease stage, and probably combination therapies. See the comprehensive page for detailed molecular mechanisms, therapeutic strategies, and complete references.